Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Narcolepsy- Market Insights, Epidemiology and Market Forecast-2023

ReportBuyer
Posted on: 10 Nov 17
Narcolepsy- Market Insights, Epidemiology and Market Forecast-2023 DelveInsight's "Narcolepsy - Market Insights, Epidemiology and Market Forecast-2023" Report provides an overview of the disease and global market size of the Narcolepsy for the 7MM (United States, EU5 (France, Germany, Italy, Spain and UK) and Japan.

PR Newswire

LONDON, Nov. 9, 2017

LONDON, Nov. 9, 2017 /PRNewswire/ -- Download the full report: https://www.reportbuyer.com/product/4348819

It also includes global historical and forecasted epidemiological data for the prevalent, diagnosed and treatable cases of Narcolepsy from 2013-2023. Narcolepsy is a chronic neurological / brain disorder which involves poor control of sleep and wakefulness. Narcolepsy is classically a tetrad of symptoms including EDS, cataplexy, sleep paralysis, and hypnagogic hallucinations. Narcolepsy affects approximately 200,000 Americans and 3 million people worldwide. Narcolepsy is not rare, but it is severely under-recognized and commonly misdiagnosed.

Narcolepsy appears throughout the world but occurrence rates vary among populations. The occurrence rate of narcolepsy is remarkably lower in Israel and quite higher in Japan compared to the United States. In Europe, the occurrence rate is found to be higher in UK and Germany than other European countries.

PROVIGIL by Cephalon, Inc and XYREM by Jazz Pharmaceuticals is the top selling drug for Narcolepsy contributing to majority of the market share. Other drugs are also being used for the treatment of Narcolepsy as secondary indication, but do not have much impact on the overall market size. We have estimated that the worldwide Narcolepsy will increase at a CAGR of 8.48% during the forecast period 2013-2023.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.

Scope
- Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
- Marketed information including available prescription drugs, its patent and exclusivity details.
- The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5 and Japan from 2013-2023.
- It also provides Market size of Narcolepsy for United States, EU5 and Japan from 2013 and forecasted Market size to 2023.

Download the full report: https://www.reportbuyer.com/product/4348819

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
https://www.reportbuyer.com

For more information: 
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

 

View original content:http://www.prnewswire.com/news-releases/narcolepsy--market-insights-epidemiology-and-market-forecast-2023-300553647.html

SOURCE ReportBuyer

PR Newswire
www.prnewswire.com

Last updated on: 10/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.